The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The In Vivo Contract Research Organization Market Expected To Reach Based On Its 2026 Value?
The in vivo contract research organization market has experienced robust growth recently. Projections indicate that this market will expand from $5.23 billion in 2025 to $5.68 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.6%. This historical expansion is primarily due to factors such as increased investment in pharmaceutical research and development, the broadening of biotechnology pipelines, the rising intricacy of drug development processes, stricter regulatory demands for preclinical information, and the accessibility of sophisticated animal models.
The in vivo contract research organization market is anticipated to show significant expansion in the upcoming years. It is projected to climb to $7.77 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This projected increase during the forecast period is fueled by several factors, including an escalating demand for quicker drug development timelines, the growing utilization of advanced in vivo disease models, the expansion of research in oncology and rare diseases, the increasing adoption of AI-enabled preclinical analytics, and heightened regulatory scrutiny of safety data. Prominent trends for this period encompass the rising outsourcing of preclinical research activities, an increasing need for specialized disease models, the wider acceptance of GLP-compliant toxicology studies, the development of more integrated preclinical service offerings, and a sharpened focus on data quality and reproducibility.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Drivers Are Fueling The Growth Of The In Vivo Contract Research Organization Market?
The increasing emphasis on personalized medicine is expected to drive the growth of the in vivo contract research organization market going forward. Personalized medicine is a medical approach that customizes treatment and prevention strategies to an individual’s genetic makeup, lifestyle, and environment to optimize health outcomes. This heightened focus on personalized medicine is attributed to the increasing accessibility and affordability of genomic sequencing technologies, as these advancements enable more accurate identification of genetic mutations, facilitating tailored therapies that improve patient outcomes and reduce trial-and-error in treatment. The growing focus on personalized medicine is therefore boosting demand in the in vivo CRO market, as customized preclinical studies using specific animal models are essential to evaluate targeted therapies and their effects on distinct genetic profiles. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the FDA approved 16 new personalized treatments in 2023, which was up from six in 2022. Personalized medicines made up more than one-third of all new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year. Consequently, the expanding focus on personalized medicine is propelling the growth of the in vivo contract research organization market.
What Segment Categories Shape The In Vivo Contract Research Organization Market Segment Landscape?
The in vivo contract research organization market covered in this report is segmented –
1) By Type: Rodent Based, Non-Rodent Based
2) By Type Of Service: Translational And IND-Enabling In Vivo Studies, Preclinical Services, Post-Approval Nonclinical Safety And Mechanistic Studies
3) By Good Laboratory Practice Type: Good Laboratory Practice Toxicology, Non Good Laboratory Practice
4) By Applications: Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Other Applications
5) By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic And Research Institutes, Government And Regulatory Bodies
Subsegments:
1) By Rodent-Based: Mice Models, Rat Models, Genetically Engineered Rodents, Immunodeficient Rodents, Humanized Rodents
2) By Non-Rodent-Based: Canine Models, Non-Human Primate Models, Swine Models, Rabbit Models, Zebrafish Models
What Trends Are Influencing The In Vivo Contract Research Organization Market?
Major companies operating in the in vivo contract research organization market are focusing on developing innovative solutions, such as advanced therapy incubator programs, to accelerate the development of next-generation therapeutics and support early-stage clinical research. An advanced therapy incubator program is a specialized initiative designed to support early-stage biotechnology companies by providing resources, mentorship, and infrastructure to accelerate the development of advanced therapies such as gene, cell, and RNA-based treatments. For instance, in April 2025, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched its inaugural advanced therapy incubator program cohort. This innovative initiative is designed to support early-stage biotech companies focused on developing next-generation therapies. Through the program, participants gain access to Charles River’s scientific expertise, state-of-the-art laboratory infrastructure, and customized in vivo models, enabling them to rapidly generate proof-of-concept data. The program also provides a real-world preclinical setting for validating therapeutic candidates, helping to shorten time-to-clinic and improve the likelihood of regulatory success. By bridging the gap between academic innovation and clinical development, the initiative plays a crucial role in advancing the field of advanced therapies.
Who Are The Companies Operating Across The In Vivo Contract Research Organization Market Value Chain?
Major companies operating in the in vivo contract research organization market are Thermo Fisher Scientific Inc, Labcorp Drug Development Inc, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc, Evotec SE, GemPharmatech Co Ltd, BIOQUAL Inc, Crown Bioscience Inc, PsychoGenics Inc, Janvier Labs SAS, Taconic Bioscience Inc, Xentech SAS, Altogen Labs Inc, AniLocus Inc, Pharmaron Beijing Co Ltd, Southern Research Institute, SRI International, Envigo RMS LLC, Horizon Discovery Group plc, Inotiv Inc, GenScript ProBio
Get The Full In Vivo Contract Research Organization Market Report:
Which Region Is The Top Contributor To The In Vivo Contract Research Organization Market By Share?
North America was the largest region in the in vivo contract research organization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vivo contract research organization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized In Vivo Contract Research Organization Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global In Vivo Contract Research Organization Market 2026, By The Business Research Company
Contract Development Manufacturing Organizations Market Report 2026
Biologics Contract Development Market Report 2026
Medical Device Contract Manufacturing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model